Germline Modification Carries Risk of Major Social Harm
By Marcy Darnovsky,
Nature
| 06. 04. 2008
Your Editorial 'New sources of sex cells' (Nature 452, 913; 2008), on the potential use of pluripotent stem-cell-derived gametes (PSCDGs) for germline genetic modification and enhancement, suggests that the prospect of stem-cell-derived gametes could trigger renewed calls for regulating human biotechnologies. In those discussions we must, as you warn, be wary of impeding basic research. But we must be equally willing to draw lines proscribing socially pernicious applications.
Germline (that is, inheritable) modification is the most socially consequential and ethically dubious application of human biotechnology; its implications have been explored from a wide range of perspectives. Most of these discussions have focused on the social meaning and repercussions of genetic manipulation of the human species, not on the moral status of human embryos. One can strongly support human-embryo research and still oppose germline modification. Conversely, some opponents of abortion rights support germline modification, so long as no embryos are destroyed in the process.
Although there may be scientific and therapeutic benefits from research on PSCDGs, the case for any such benefits from using these cells for human germline modification is...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...